|
|
|
|
A personalized gene-editing therapy was developed in months, showcasing how collaboration, manufacturing innovation, and regulatory alignment can accelerate treatments for rare diseases.
|
|
|
|
|
Early research choices shape outcomes. Focusing on reproducibility, scalability, regulatory fit, and supply stability early cuts risk, prevents delays, and supports smoother development progress.
|
|
|
|
|
See how Codex HiCap RNA Polymerase supports the production of high-performance synthetic mRNA, paving the way for next-generation mRNA therapies and vaccines.
|
|
|
|
|
|
|
Integrated genomic medicine reduces risk and timelines, improving consistency across modalities from research through clinical and commercial stages.
|
|
|
|
|
Reducing immunogenic RNA byproducts while preserving yield is key for mRNA manufacturing. Optimized transcription and capping streamline processing, cut costs, and enable scalable workflows.
|
|
|
